CMS will provide states monthly reports of beneficiaries whose citizenship or immigration status cannot be confirmed. States are expected to take “appropriate actions” including limiting coverage, the agency said.
CMS initiative targets undocumented immigrants in Medicaid Read More »
The committee will oversee areas where UnitedHealth has struggled or faced public scrutiny: underwriting and forecasting, regulatory relationships, reputational matters and M&A.
UnitedHealth forms new ‘public responsibility’ board committee Read More »
The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto parts, pharmaceuticals and semiconductors.
The FDA updated its list of breakthrough devices as medtech groups lobby for faster Medicare coverage of products with the designation.
More than 1,100 devices have received the FDA’s breakthrough designation Read More »
Meenal Sethna will join the infusion therapy provider in October. She’ll succeed former CFO Michael Shapiro, who will continue to work in a transition role through March.
Improving health data exchange is a worthy goal, but the initiative so far includes few details on how it will work — and has plenty of barriers to overcome, experts say.
White House data sharing plan boasts big ambitions, but has scant details Read More »
President Donald Trump first threatened pharma tariffs in February and recently said they were imminent. Johnson & Johnson’s new investment adds to a $55 billion pledge made by the company in March.
J&J Adds $2B to US Manufacturing Commitment Amid Trump’s Protracted Tariff Threats Read More »
Stealth BioTherapeutics originally submitted elamipretide for approval in January 2024, only to receive a rejection in May of this year. In addition to accepting the biotech’s resubmission, the FDA has promised to take action on the candidate by Sept. 26.
Stealth’s Flight Path Returns to FDA for Rejected Barth Drug Read More »
In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s potential to reduce preclinical costs with Mutlu Dogruel, VP of AI and Mark Mackey, CSO of Cresset.
Why AI Won’t Save the 90% of Clinical Trials That Still Fail Read More »
Washington has had notable life sciences job growth over the past 10 years, according to a Life Science Washington report. The association’s CEO and a biopharma CEO discuss what makes the state stand out, including its talent pool, AI leadership and entrepreneurship support.
Washington’s Life Sciences Scene Moves Beyond Research Roots Read More »
